<div><div></div><div><span><p><span>Karyopharm Therapeutics Inc. reported first-quarter 2026 results with revenue rising to $35.1M and a narrowed net loss of $22.4M versus the year‑ago quarter, driven by stronger U.S. sales of XPOVIO/NEXPOVIO and ongoing clinical progress.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue: $35.1M for Q1 2026, up from $30.0M in Q1 2025 (17% YoY).</span></li><li><span>Net income: Net loss $22.4M for Q1 2026 versus net loss $23.5M in Q1 2025 (loss narrowed by $1.1M, (5%) YoY).</span></li><li><span>Diluted EPS: Diluted net loss per share $(1.24) for Q1 2026 vs $(2.77) in Q1 2025 (improved YoY).</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue Growth: Net revenue rose 17% YoY to $35.1M, led by a 39% increase in U.S. XPOVIO product sales.</span></li><li><span>Brand Momentum: XPOVIO/NEXPOVIO expanding global approvals and commercial availability across more than 50 territories.</span></li><li><span>Clinical Milestones: SENTRY Phase 3 met its spleen reduction endpoint and showed a topline overall‑survival signal; the company plans FDA engagement.</span></li><li><span>Pipeline Progress: Phase 3 programs XPORT-EC-042 (endometrial cancer) and EMN29 (myeloma) are completed or enrolling, with topline data expected in the second half of 2026.</span></li><li><span>Operational Focus: U.S. commercialization supported by sales forces, nurse liaisons, market access efforts and the KaryForward patient support program.</span></li></ul><p><span>Original SEC Filing: </span>Karyopharm Therapeutics Inc. [ KPTI ] - 10-Q - May. 14, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

KPTI

<p>Karyopharm Therapeutics Inc. reported Q1 2026 revenue of $35.1M, a 17% increase from Q1 2025, with a narrowed net loss of $22.4M. Diluted EPS improved to $(1.24) from $(2.77) year-over-year. The growth was driven by a 39% rise in U.S. XPOVIO sales and ongoing clinical advancements, including successful Phase 3 trials. The company is expanding its product's global availability and focusing on U.S. commercialization efforts.</p>

TradingView

Karyopharm Therap

SPDR S&P Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VG Health

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

VanEck Biotech ETF

Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary